Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 6/20 | 0.61 |
| ▸ | THRA | P10827 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.51 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.50 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.49 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4534864 | 0.93 | SMPD1 (0.60) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL9565566 | 0.92 | SMPD1 (0.67) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL967401 | 0.92 | SMPD1 (0.67) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL9304902 | 0.92 | SMPD1 (0.67) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL24950547 | 0.92 | SMPD1 (0.67) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL7335792 | 0.90 | SMPD1 (0.64) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL4531499 | 0.88 | SMPD1 (0.53) | SMPD1THRATHRBMGLL | |
| SCHEMBL9307263 | 0.86 | SMPD1 (0.76) | SMPD1THRATHRBMGLLCNR2 | |
| SCHEMBL9307505 | 0.86 | SMPD1 (0.67) | SMPD1THRATHRBMGLLPLA2G4B | |
| SCHEMBL14930509 | 0.86 | SMPD1 (0.67) | SMPD1THRATHRBMGLLPLA2G4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176995-A1 | Soluble fullerene derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2009-07-09 | — | — | US | disclosed |
| US-20090176995-A1 | Soluble fullerene derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA INSTITUTE OF TECHNOLOGY (JP) | 2009-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176995-A1 | Soluble fullerene derivatives | SOD1, EPCAM, NDUFV2 | SMPD1 4453/4885THRA 4590/4885THRB 4784/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.